This page shows the latest leukaemia news and features for those working in and with pharma, biotech and healthcare.
Amgen’s treatment has already been approved for use in adult patients with non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). ... Riabni is not currently
In addition to refractory follicular lymphoma, Kymriah is also approved to treat paediatric and young adults up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL)
As a consequence, enrolment in the US can resume for the studies into the therapies, which treat both myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). ... One in three people with the condition will progress to AML, making it one of the
for patients with myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) and AML patients unable to receive intensive chemotherapy.
The first two programmes involve an acute myeloid leukaemia programme coupled with a programme in multiple myeloma.
Bone marrow transplants for the treatment of leukaemia and other blood cancers have a long history, with the first procedure in 1957 in identical twins leading its pioneer, Dr E Donnall
More from news
Approximately 76 fully matching, plus 434 partially matching documents found.
The product underwent its first phase 1 trial test in January 2020 with a patient who was suffering from acute myeloid leukaemia.
symptoms including bladder/ bowel dysfunction, high blood pressure and leukaemia, and can reduce life expectancy by up to 15 years.
3. Novartis’ OMB-157 is a monthly or 12-weekly subcutaneous formulation of the anti-CD20 monoclonal antibody Arzerra (which is indicated as an intravenous infusion for chronic lymphocytic leukaemia) in
DS-8201 is central to that effort, but it’s also hoping for strong support from other pipeline drugs like quizartinib for relapsed or refractory FLT3-positive acute myeloid leukaemia (AML) –
An 11-month old baby suffering from CD19-positive acute lymphoblastic leukaemia (ALL) was treated with modified donor T cells that had been engineered to attack leukaemia cells.
More from intelligence
Approximately 1 fully matching, plus 49 partially matching documents found.
As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells.
She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its
Bergonio moves from Novartis, where he served as an expert clinical manager in the Swiss firm's oncology global development unit, specialising in acute myeloid leukaemia.
breast cancer, leukaemia, lung cancer and prostate cancer.
In his new role at Akinion Pharmaceuticals Dr Jones will oversee a company focused on acute myeloid leukaemia and its lead candidate drug AKN-028, a small molecule kinase inhibitor currently
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
Precision medicines already exist; imatinib works to treat leukaemia only when the cancer cells have a particular genetic makeup, Sotorasib targets a specific mutation in people with lung cancer to halt
For the Pip award, which aimed to promote the work of the Elimination of Leukaemia Fund (ELF) Mind and Body Service, Frontera was awarded for the ‘White Cell’.
The therapy was trialled in paediatric and young adult lymphoblastic leukaemia patients suffering from the most aggressive forms of the disease.
We have recently developed an above-brand app called “CML Life” which is for patients with chronic myeloid leukaemia.
There are a number of trials being undertaken throughout the world, but the first licensed product, Novartis’ Kymriah, is now available for the treatment of leukaemia and is live at GOSH.
More from PMHub
Approximately 2 fully matching, plus 15 partially matching documents found.
Viseven is a Global MarTech Services Provider for Pharma and Life Sciences Industries...